Terms: = Ovarian cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717
85 results:
1. WP1066, a small molecule inhibitor of STAT3, chemosensitizes paclitaxel-resistant ovarian cancer cells to paclitaxel by simultaneously inhibiting the activity of STAT3 and the interaction of STAT3 with Stathmin.
Yang J; Li N; Zhao X; Guo W; Wu Y; Nie C; Yuan Z
Biochem Pharmacol; 2024 Mar; 221():116040. PubMed ID: 38311257
[TBL] [Abstract] [Full Text] [Related]
2. The association between hepatic viral infections and cancers: a cross-sectional study in the Taiwan adult population.
Maliko M; Su FH; Kamiza AB; Su MJ; Yeh CC
Clin Exp Med; 2024 Jan; 24(1):20. PubMed ID: 38279980
[TBL] [Abstract] [Full Text] [Related]
3. ANGPTL4 accelerates ovarian serous cystadenocarcinoma carcinogenesis and angiogenesis in the tumor microenvironment by activating the jak2/STAT3 pathway and interacting with ESM1.
Li YK; Gao AB; Zeng T; Liu D; Zhang QF; Ran XM; Tang ZZ; Li Y; Liu J; Zhang T; Shi GQ; Zhou WC; Zou WD; Peng J; Zhang J; Li H; Zou J
J Transl Med; 2024 Jan; 22(1):46. PubMed ID: 38212795
[TBL] [Abstract] [Full Text] [Related]
4. [Etiological analysis of a patient with multiple primary malignant neoplasms].
Shi PJ; Li YB; Xiao HP
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(47):3848-3851. PubMed ID: 38123227
[TBL] [Abstract] [Full Text] [Related]
5. Integrated bioinformatics and network pharmacology to explore the therapeutic target and molecular mechanisms of Bailing capsule on polycystic ovary syndrome.
Guan HR; Li B; Zhang ZH; Wu HS; He XL; Dong YJ; Su J; Lv GY; Chen SH
BMC Complement Med Ther; 2023 Dec; 23(1):458. PubMed ID: 38102584
[TBL] [Abstract] [Full Text] [Related]
6. 3'-Hydroxypterostilbene Potently Suppresses Tumor Growth via Inhibiting the Activation of the jak2/STAT3 Pathway in ovarian Clear Cell Carcinoma.
Koh YC; Huang WZ; Nagabhushanam K; Ho CT; Pan MH
Mol Nutr Food Res; 2024 Jan; 68(1):e2300108. PubMed ID: 37876143
[TBL] [Abstract] [Full Text] [Related]
7. SPIB Knockdown Inhibits the Immune Escape of ovarian cancer Cells by Reducing PD-L1 (CD274) Expression and Inactivating the JAK/STAT Pathway.
Gu W; Qi G; Chen L
Iran J Immunol; 2023 Sep; 20(3):335-347. PubMed ID: 37452634
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Dvořák J; Němejcová K; Matěj R; Laco J; Drozenová J; Fabian P; Hausnerová J; Méhes G; Škapa P; Švajdler M; Cibula D; Frühauf F; Bártů MK; Dundr P
Diagn Pathol; 2023 Jun; 18(1):72. PubMed ID: 37303048
[TBL] [Abstract] [Full Text] [Related]
9. Ginkgetin suppresses ovarian cancer growth through inhibition of jak2/STAT3 and MAPKs signaling pathways.
Wu L; Qian C; Zhang W; Shi M; Chen X; Wang Y; Lin F
Phytomedicine; 2023 Jul; 116():154846. PubMed ID: 37172479
[TBL] [Abstract] [Full Text] [Related]
10. OTX1 silencing suppresses ovarian cancer progression through inhibiting the JAK/STAT signaling.
Zhang Q; Li X; Ren L; Gu X; Xiao N; Li N
Tissue Cell; 2023 Jun; 82():102082. PubMed ID: 37027968
[TBL] [Abstract] [Full Text] [Related]
11. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
12. Antiovarian cancer mechanism of esculetin: inducing G0/G1 arrest and apoptosis via jak2/STAT3 signalling pathway.
Yin W; Fu X; Chang W; Han L; Meng J; Cao A; Ren X; Fan Z; Zhou S
J Pharm Pharmacol; 2023 Jan; 75(1):87-97. PubMed ID: 36332079
[TBL] [Abstract] [Full Text] [Related]
13. Hyperandrogenism due to ovarian Leydig cell tumour presenting with polycythaemia.
Demir AY; Blok BB; Brinkhuis EA; Oldenburg-Ligtenberg CP
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35840164
[TBL] [Abstract] [Full Text] [Related]
14. CircAHNAK upregulates EIF2B5 expression to inhibit the progression of ovarian cancer by modulating the jak2/STAT3 signaling pathway.
He SL; Zhao X; Yi SJ
Carcinogenesis; 2022 Nov; 43(10):941-955. PubMed ID: 35710311
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of Natural Ursane-type SENP1 Inhibitors and the Platinum Resistance Reversal Activity Against Human ovarian cancer Cells: A Structure-Activity Relationship Study.
Wei H; Guo J; Sun X; Gou W; Ning H; Shang H; Liu Q; Hou W; Li Y
J Nat Prod; 2022 May; 85(5):1248-1255. PubMed ID: 35500202
[TBL] [Abstract] [Full Text] [Related]
16. Arachidonic acid, a clinically adverse mediator in the ovarian cancer microenvironment, impairs JAK-STAT signaling in macrophages by perturbing lipid raft structures.
Hammoud MK; Dietze R; Pesek J; Finkernagel F; Unger A; Bieringer T; Nist A; Stiewe T; Bhagwat AM; Nockher WA; Reinartz S; Müller-Brüsselbach S; Graumann J; Müller R
Mol Oncol; 2022 Sep; 16(17):3146-3166. PubMed ID: 35451191
[TBL] [Abstract] [Full Text] [Related]
17. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
18. jak2-Mediated Phosphorylation of Stress-Induced Phosphoprotein-1 (STIP1) in Human Cells.
Chao A; Liao MJ; Chen SH; Lee YS; Tsai CN; Lin CY; Tsai CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269562
[TBL] [Abstract] [Full Text] [Related]
19. Design, synthesis and biological evaluation of antitumor platinum(II) agents conjugated with non-steroidal anti-inflammatory drug species.
Zang J; Zhang B; Wang Y; Wang X; Gou S
Bioorg Chem; 2022 Mar; 120():105633. PubMed ID: 35091288
[TBL] [Abstract] [Full Text] [Related]
20. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With ovarian cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract] [Full Text] [Related]
[Next]
